Which peptides are studied in relation to de novo lipogenesis?

De novo lipogenesis (DNL) is the metabolic pathway by which acetyl-CoA is converted, through a series of enzymatic steps, into palmitate and other saturated fatty acids. The pathway is centred on the enzyme family that includes acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN), with downstream desaturation and elongation steps. In the research literature, the peptides most frequently studied in relation to DNL are not a single compound class but a set of signalling peptides and peptide hormones — including insulin, glucagon, glucagon-like peptide-1 (GLP-1), fibroblast growth factor 21 (FGF21), growth hormone and several growth-hormone secretagogues — together with peptide-based research reagents used to probe the pathway in cultured cells and animal models.

The work centres on the insulin/glucagon receptor axis and its downstream transcriptional control of lipogenic gene expression, principally through sterol regulatory element-binding protein 1c (SREBP-1c) and carbohydrate-responsive element-binding protein (ChREBP). Where the evidence block supplies identifiers, they are given below; where it does not, no sequence, formula or molecular weight is asserted here.

Research Studies

Insulin and hepatic SREBP-1c-driven lipogenesis

Insulin is the most extensively studied peptide in relation to hepatic DNL. In insulin-resistant states, including pre-diabetes and type 2 diabetes mellitus, the normal suppression of hepatic glucose output is lost while lipogenic gene transcription remains elevated. A registered study of diet impact on hepatic transcriptomics and lipidomics in pre-diabetes describes non-alcoholic fatty liver disease (NAFLD) as excessive lipid accumulation within hepatocytes in the absence of significant alcohol consumption or other chronic liver disease causes, affecting 25% to 30% of the global population and nearly one third of the population in North America [1]. The same source notes that these patients typically present with hepatic steatosis on imaging, elevated liver enzymes and clinical features of insulin resistance, including pre-diabetes, type 2 diabetes mellitus, arterial hypertension, dyslipidemia and visceral obesity [1]. This is a human observational and interventional context, not a peptide-administration study.

FGF21 and lipid handling in metabolic models

Fibroblast growth factor 21 is a peptide hormone studied for its effects on lipid metabolism across hepatic and adipose tissue. It appears in the DNL literature chiefly as a comparator or modifier of lipogenic flux rather than as a direct enzymatic component of the pathway. The evidence block does not supply quantitative FGF21 data, so no effect size is reported here.

GLP-1 receptor agonists and hepatic lipid endpoints

GLP-1 is an incretin peptide, and GLP-1 receptor agonists are studied in relation to hepatic steatosis and lipid endpoints in metabolic disease. The relevant human population in the evidence block is the NAFLD and insulin-resistant cohort described above [1]. Findings in that population concern transcriptomic and lipidomic responses to diet, not peptide dosing.

FASN as the rate-limiting enzyme and its peptide-adjacent regulation

Fatty acid synthase (FASN) is the rate-limiting enzyme of de novo lipogenesis. In arrhythmogenic cardiomyopathy (ACM), a heritable disease caused by desmosomal gene mutations and marked by progressive myocardial loss and fibrofatty replacement, FASN was reported to be upregulated in cardiomyocytes of ACM patients and of a corresponding model [2]. The same work reported that FASN-mediated de novo lipogenesis promoted ceramide accumulation and myocardial damage in that disease context [2]. This is a cardiac disease model, not a hepatic one, and the finding is specific to the ACM population studied.

Growth hormone, IGF-1 and lipogenic gene expression

Growth hormone and insulin-like growth factor 1 are peptide hormones that influence hepatic lipid handling, and they are studied as upstream modulators of lipogenic transcription. The evidence block does not contain a study reporting a specific DNL effect size for either peptide, so no such claim is made here.

Peptide reagents used to probe ACC and FASN activity

In cell-culture work, short peptide sequences and peptide-based inhibitors are used as research reagents to interrogate ACC and FASN activity. These are laboratory tools rather than therapeutic candidates. No specific reagent sequence or potency value is supplied in the evidence block, and none is asserted.

Model comparison across DNL peptide studies

The table below summarises the model context for the findings that the evidence block supports. It is deliberately sparse: only claims traceable to the cited sources are included.

Where the evidence is animal-only or in vitro

Two limitations should be stated plainly. First, the ACM finding on FASN-mediated DNL and ceramide accumulation derives from patient cardiomyocytes and a corresponding model, and is therefore not a generalisable statement about DNL in healthy tissue [2]. Second, the pre-diabetes transcriptomic and lipidomic work concerns a human cohort but addresses dietary impact rather than peptide administration [1]. No human dose-response data for any peptide in relation to DNL is present in the evidence block.

If you are reading this for personal health reasons

The materials described on this page are sold for laboratory research use only. We do not provide dosing, administration or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Diet Impact on Hepatic Transcriptomics and Lipidomics in Pre-diabetes — ClinicalTrials.gov, public domain.
• [2] FASN-mediated de novo lipogenesis promotes ceramide accumulation and myocardial damage in arrhythmogenic cardiomyopathy — Europe PMC.